Skip to content

Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients: A Prospective Cohort Study

Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients: A Prospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123754
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Interventions

Overweight/Obesity Group:NA

Sponsors

The Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–65 years with ASA physical status I–III; 2. Body Mass Index (BMI) meeting the following grouping criteria: Normal control group (18.5 = 24.0 kg/m²); 3. Voluntary participation with written informed consent approved by the Ethics Committee; 4. No cognitive or verbal communication impairments, with the ability to fully cooperate with the study procedures; 5. Scheduled for elective surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Severe organ dysfunction, including severe hepatic or renal insufficiency, unstable coronary syndrome, uncontrolled hypertension, and other severe cardiovascular diseases; 2. History of chronic pain or long-term use of opioids/sedatives; preoperative use of potent CYP3A inhibitors or inducers; 3. Contraindications to body composition measurement via Bioelectrical Impedance Analysis (BIA), including abdominal wall stoma, massive ascites, limb amputation/absence, and presence of cardiac pacemakers or implantable cardioverter-defibrillators (ICDs); 4. Women who were pregnant or breastfeeding were excluded from the study; 5. Known hypersensitivity or allergy to study medications; 6. Any other condition deemed by the investigator to make the patient unsuitable for participation, including but not limited to severe psychiatric disorders or legal restrictions.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic Parameters of Sufentanil (e.g., Clearance, Volume of Distribution, Half-life);The occurrence rate of adverse events during surgery and the postoperative period;

Secondary

MeasureTime frame
ody Composition Parameters (Visceral Fat Area, Waist Circumference, Muscle Mass, Fat Mass);Anesthesia Recovery Time and Extubation Time;Postoperative Rescue Analgesic Consumption;

Countries

China

Contacts

Public ContactLi Ting

The Second Affiliated Hospital of Wenzhou Medical University

Liting1021@aliyun.com+86 577 85676822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026